MXPA06007519A - Treatment of coronary or peripheral ischemia. - Google Patents

Treatment of coronary or peripheral ischemia.

Info

Publication number
MXPA06007519A
MXPA06007519A MXPA06007519A MXPA06007519A MXPA06007519A MX PA06007519 A MXPA06007519 A MX PA06007519A MX PA06007519 A MXPA06007519 A MX PA06007519A MX PA06007519 A MXPA06007519 A MX PA06007519A MX PA06007519 A MXPA06007519 A MX PA06007519A
Authority
MX
Mexico
Prior art keywords
coronary
treatment
product
relates
peripheral ischemia
Prior art date
Application number
MXPA06007519A
Other languages
Spanish (es)
Inventor
Andre Uzan
Alexis Caron
Original Assignee
Centelion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centelion filed Critical Centelion
Publication of MXPA06007519A publication Critical patent/MXPA06007519A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to novel methods of treating a patient having peripheral and/or coronary ischemic syndrome and also relates to a product comprising an expression vector encoding an angiogenic growth factor and a heparin compound, wherein the product is capable of acting in a synergistic manner to promote angiogenesis and arteriogenesis in skeletal and cardiac muscles.
MXPA06007519A 2003-12-29 2004-12-29 Treatment of coronary or peripheral ischemia. MXPA06007519A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53299303P 2003-12-29 2003-12-29
PCT/EP2004/014910 WO2005063807A2 (en) 2003-12-29 2004-12-29 Treatment of coronary or peripheral ischemia

Publications (1)

Publication Number Publication Date
MXPA06007519A true MXPA06007519A (en) 2007-05-23

Family

ID=34738851

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06007519A MXPA06007519A (en) 2003-12-29 2004-12-29 Treatment of coronary or peripheral ischemia.

Country Status (8)

Country Link
EP (1) EP1699819A2 (en)
JP (1) JP2007536909A (en)
KR (1) KR20070006714A (en)
AU (1) AU2004309090A1 (en)
CA (1) CA2550727A1 (en)
MX (1) MXPA06007519A (en)
WO (1) WO2005063807A2 (en)
ZA (1) ZA200606268B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220122774A (en) * 2007-09-26 2022-09-02 셀룰래리티 인코포레이티드 Angiogenic cells from human placental perfusate
EP2558115B1 (en) 2010-04-16 2019-07-31 The Salk Institute for Biological Studies Methods for treating metabolic disorders using fgf
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
CA2928135A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Mutated fibroblast growth factor (fgf) 1 and methods of use
AU2016344134A1 (en) 2015-10-30 2018-05-31 Salk Institute For Biological Studies Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
JP7333919B2 (en) * 2017-09-05 2023-08-28 エクセル メッド、エルエルシー Heparin composition for treating ischemia
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733871A (en) * 1991-11-08 1998-03-31 The General Hospital Corporation Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
ATE306546T1 (en) * 1996-08-23 2005-10-15 Ludwig Inst Cancer Res RECOMBINANT VASCULAR ENDOTHELIAL CELL GROWTH FACTOR D (VEGF-D)
US6395707B1 (en) * 1997-02-14 2002-05-28 Genentech, Inc. Methods of treatment utilizing variants of vascular endothelial cell growth factor
US7252818B2 (en) * 1998-07-24 2007-08-07 Cardiovascular Biotherapeutics, Inc. Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
IL133318A0 (en) * 1999-12-05 2001-04-30 Yeda Res & Dev Proteoglycans and pharmaceutical compositions comprising them
US20050187150A1 (en) * 2001-10-31 2005-08-25 New York University Structure-based design and synthesis of FGF inhibitors and FGF modulator compounds
EA200501846A1 (en) * 2003-06-05 2007-12-28 Сентельон PLASMIDA, CODIFYING FACTOR OF GROWTH OF FIBROBLASTES, FOR THE TREATMENT OF ANGIOGENIC DEFECTS ASSOCIATED WITH HYPROCHOLESTEREMIA OR DIABETES

Also Published As

Publication number Publication date
EP1699819A2 (en) 2006-09-13
WO2005063807A2 (en) 2005-07-14
ZA200606268B (en) 2008-04-30
WO2005063807A3 (en) 2005-09-29
JP2007536909A (en) 2007-12-20
AU2004309090A1 (en) 2005-07-14
KR20070006714A (en) 2007-01-11
CA2550727A1 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
GB0223038D0 (en) Therapeutic compounds
CA2120303A1 (en) Cyclic adhesion inhibitors
GB0119011D0 (en) Treatment of nail infections
MXPA02011339A (en) Treatment of acute coronary syndrome with glp 1.
ATE508735T1 (en) PULMONARY ADMINISTRATION OF AMINOGLYCOSIDES
ATE428456T1 (en) ANTIMICROBIAL MEDICAL ARTICLES
CY1105127T1 (en) COMPOSITION FOR THE PREVENTION OF CARDIAC DISEASES
ATE462424T1 (en) THERAPEUTIC USE OF NEBULATED S-NITROSOGLUTATHIONE IN CYSTIC FIBROSIS
MXPA02002118A (en) Compositions containing legume products.
MXPA06007519A (en) Treatment of coronary or peripheral ischemia.
MXPA02002117A (en) Use of legume products for the treatment of external aggressions.
MXPA02002119A (en) Legume products.
WO2003059258A3 (en) Compositions and methods for treating heart failure
WO2003057820A3 (en) Peptide activators of vegf
CY1109995T1 (en) COMPOSITIONS CONTENTS OF SOYA PRODUCTS
BR0209541A (en) Use of 2-phenyl-substituted imidazotriazinones
WO2003059265A3 (en) Compositions and methods for treating heart failure
ATE427107T1 (en) A NEW USE OF DEFERIPRONE
NO20000016L (en) Cyclic azapeptides with angiogenic activity
MXPA05004133A (en) 4-methylhexanoic kahalaide f compound.
ATE340572T1 (en) BENZAZOLE DERIVATIVES FOR THE TREATMENT OF SCLERODERMA
WO2003000009A3 (en) Stimulation of vascularization with vegf-b
DE69924747D1 (en) USE OF LIMESTONE FOR FOOD AND COSMETICS
EE200300495A (en) Preparations of 3,7-diazabicyclo [3.3.1], methods for their preparation and their use in the prophylaxis or treatment of cardiac arrhythmias
MXPA05011428A (en) Method of treating atrial fibrillation or atrial flutter.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal